Ciclosporin liposomal - PARI Pharma

Drug Profile

Ciclosporin liposomal - PARI Pharma

Alternative Names: Ciclosporin inhalation - PARI Pharma; L-CsA - PARI Pharma

Latest Information Update: 15 Oct 2015

Price : $50

At a glance

  • Originator PARI
  • Developer PARI GmbH
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiolitis obliterans
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bronchiolitis obliterans

Most Recent Events

  • 15 Oct 2015 Discontinued - Phase-III for Bronchiolitis Obliterans (Prevention) in Austria (Inhalation)
  • 15 Oct 2015 Discontinued - Phase-III for Bronchiolitis Obliterans (Prevention) in Spain (Inhalation)
  • 15 Oct 2015 Discontinued - Phase-III for Bronchiolitis Obliterans (Prevention) in Denmark (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top